Corvus Pharmaceuticals (CRVS) News Today $2.58 +0.27 (+11.69%) (As of 07/26/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 September 2021 August 2021 Time Period July 17, 2024 | americanbankingnews.comCorvus Pharmaceuticals (NASDAQ:CRVS) Stock Passes Below 50 Day Moving Average of $2.02July 17, 2024 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Shares Pass Below 50 Day Moving Average of $2.02Corvus Pharmaceuticals (NASDAQ:CRVS) Share Price Passes Below 50-Day Moving Average of $2.02July 6, 2024 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Share Price Passes Below 50 Day Moving Average of $1.98Corvus Pharmaceuticals (NASDAQ:CRVS) Stock Price Crosses Below 50 Day Moving Average of $1.98June 16, 2024 | marketbeat.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Sees Large Growth in Short InterestCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) was the target of a significant growth in short interest in May. As of May 31st, there was short interest totalling 1,520,000 shares, a growth of 17.8% from the May 15th total of 1,290,000 shares. Based on an average daily trading volume, of 235,300 shares, the days-to-cover ratio is currently 6.5 days.June 3, 2024 | marketbeat.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Sees Large Drop in Short InterestCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) saw a large drop in short interest during the month of May. As of May 15th, there was short interest totalling 1,290,000 shares, a drop of 5.1% from the April 30th total of 1,360,000 shares. Based on an average daily volume of 248,500 shares, the days-to-cover ratio is currently 5.2 days.May 31, 2024 | investorplace.comThe 2024 Millionaire's Club: 3 Penny Stocks to Buy NowMay 30, 2024 | globenewswire.comCorvus Pharmaceuticals to Present at the Jefferies Global Health ConferenceMay 20, 2024 | stockhouse.comSHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Corvus Pharmaceuticals, Inc. (CRVS) and Encourages Investors to Contact the FirmMay 15, 2024 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Shares Pass Above 50 Day Moving Average of $1.77Corvus Pharmaceuticals (NASDAQ:CRVS) Share Price Crosses Above 50-Day Moving Average of $1.77May 12, 2024 | finance.yahoo.com13 Penny Stocks with Insider Buying in 2024May 10, 2024 | finance.yahoo.comInsider Spends US$1m Buying More Shares In Corvus PharmaceuticalsMay 8, 2024 | insidertrades.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Insider Purchases $34,600.00 in StockMay 7, 2024 | marketbeat.comWilliam Benton Jones Purchases 20,000 Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) StockCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) insider William Benton Jones acquired 20,000 shares of the stock in a transaction dated Monday, May 6th. The shares were purchased at an average price of $1.73 per share, for a total transaction of $34,600.00. Following the completion of the transaction, the insider now owns 153,773 shares of the company's stock, valued at approximately $266,027.29. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.May 7, 2024 | finance.yahoo.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call TranscriptMay 7, 2024 | finanznachrichten.deCorvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 7, 2024 | finance.yahoo.comQ1 2024 Corvus Pharmaceuticals Inc Earnings CallMay 7, 2024 | marketbeat.comOppenheimer Increases Corvus Pharmaceuticals (NASDAQ:CRVS) Price Target to $8.00Oppenheimer upped their target price on shares of Corvus Pharmaceuticals from $7.00 to $8.00 and gave the stock an "outperform" rating in a research report on Tuesday.May 7, 2024 | finance.yahoo.comCorvus Pharmaceuticals Inc (CRVS) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 6, 2024 | globenewswire.comCorvus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 3, 2024 | marketbeat.comCorvus Pharmaceuticals (CRVS) Set to Announce Earnings on MondayCorvus Pharmaceuticals (NASDAQ:CRVS) will be releasing earnings after the market closes on Monday, May 6, Zacks reports.May 2, 2024 | globenewswire.comCorvus Pharmaceuticals to Provide Business Update and First Quarter 2024 Financial Results on May 6, 2024May 2, 2024 | globenewswire.comCorvus Pharmaceuticals Announces Pricing of $30.6 Million Registered Direct OfferingApril 24, 2024 | finance.yahoo.comCorvus Pharmaceuticals, Inc. (CRVS)April 17, 2024 | finance.yahoo.comHere's Why Corvus (CRVS) is Poised for a Turnaround After Losing -25% in 4 WeeksApril 16, 2024 | marketbeat.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Down 6.0% in MarchCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) was the target of a significant decrease in short interest during the month of March. As of March 31st, there was short interest totalling 1,400,000 shares, a decrease of 6.0% from the March 15th total of 1,490,000 shares. Currently, 3.8% of the shares of the stock are sold short. Based on an average trading volume of 212,900 shares, the days-to-cover ratio is currently 6.6 days.April 9, 2024 | globenewswire.comCorvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic DermatitisApril 4, 2024 | marketbeat.comCorvus Pharmaceuticals, Inc. to Post FY2024 Earnings of ($0.35) Per Share, Cantor Fitzgerald Forecasts (NASDAQ:CRVS)Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Free Report) - Research analysts at Cantor Fitzgerald lifted their FY2024 EPS estimates for shares of Corvus Pharmaceuticals in a report issued on Monday, April 1st. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will earn ($0.35) peApril 1, 2024 | marketbeat.comCantor Fitzgerald Reaffirms Overweight Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Corvus Pharmaceuticals in a research note on Monday.March 27, 2024 | marketbeat.comMizuho Reiterates Neutral Rating for Corvus Pharmaceuticals (NASDAQ:CRVS)Mizuho reaffirmed a "neutral" rating and set a $3.50 target price on shares of Corvus Pharmaceuticals in a research report on Wednesday.March 21, 2024 | seekingalpha.comCorvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | finance.yahoo.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call TranscriptMarch 21, 2024 | finanznachrichten.deCorvus Pharmaceuticals, Inc.: Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 20, 2024 | marketbeat.comCorvus Pharmaceuticals (NASDAQ:CRVS) Price Target Lowered to $7.00 at OppenheimerOppenheimer cut their price target on Corvus Pharmaceuticals from $8.00 to $7.00 and set an "outperform" rating for the company in a research note on Wednesday.March 20, 2024 | finance.yahoo.comQ4 2023 Corvus Pharmaceuticals Inc Earnings CallMarch 19, 2024 | stockhouse.comCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 19, 2024 | globenewswire.comCorvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsMarch 18, 2024 | marketbeat.comCorvus Pharmaceuticals (CRVS) Set to Announce Quarterly Earnings on TuesdayCorvus Pharmaceuticals (NASDAQ:CRVS) will be releasing earnings on Tuesday, March 19, Yahoo Finance reports.March 16, 2024 | finance.yahoo.comCRVS Apr 2024 4.000 putMarch 13, 2024 | globenewswire.comCorvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024March 9, 2024 | finance.yahoo.comWe Think Corvus Pharmaceuticals (NASDAQ:CRVS) Needs To Drive Business Growth CarefullyMarch 4, 2024 | marketbeat.comCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Short Interest Down 8.0% in FebruaryCorvus Pharmaceuticals, Inc. (NASDAQ:CRVS - Get Free Report) was the target of a large decline in short interest in February. As of February 15th, there was short interest totalling 1,270,000 shares, a decline of 8.0% from the January 31st total of 1,380,000 shares. Approximately 3.4% of the shares of the stock are short sold. Based on an average trading volume of 206,300 shares, the short-interest ratio is currently 6.2 days.February 17, 2024 | finance.yahoo.comCRVS Mar 2024 3.000 putFebruary 12, 2024 | msn.comCorvus Edges up on Disclosing DataFebruary 12, 2024 | finance.yahoo.comCorvus' (CRVS) Lymphoma Drug Gets Orphan Status, Stock UpFebruary 8, 2024 | marketwatch.comCorvus Pharmaceuticals Shares Rise on Orphan Drug DesignationFebruary 8, 2024 | msn.comCorvus lymphoma drug gets FDA orphan drug statusFebruary 8, 2024 | finance.yahoo.comCorvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell LymphomaFebruary 6, 2024 | finance.yahoo.comCorvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business OfficerJanuary 23, 2024 | finance.yahoo.comCorvus Pharmaceuticals Announces the Passing of Board Member Edith P. MitchellJanuary 5, 2024 | finance.yahoo.comIndividual investors in Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) are its biggest bettors, and their bets paid off as stock gained 20% last week Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address “Generational Bull Run” Incoming (Ad)LIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event. You can find out what they are by clicking here now. CRVS Media Mentions By Week CRVS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRVS News Sentiment▼1.440.62▲Average Medical News Sentiment CRVS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRVS Articles This Week▼21▲CRVS Articles Average Week Get Corvus Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Oncolytics Biotech News Enlivex Therapeutics News Orgenesis News Aytu BioPharma News Contineum Therapeutics News Fulcrum Therapeutics News Lexicon Pharmaceuticals News Erasca News Annexon News PureTech Health News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRVS) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corvus Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Corvus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.